Navigation Links
Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients
Date:2/6/2008

rade 3/4 elevated total bilirubin reported among atazanavir recipients in each of the groups, respectively. There were no opportunistic infections reported in the vicriviroc groups compared to two in the control group, and no systemic malignancies reported in any of the groups in the 48- week study.

These results supported the selection of the 30 mg once-daily vicriviroc dose for use in ongoing Phase III clinical studies.

About Vicriviroc Ongoing Phase III Studies

Building on the results of the VICTOR-E1 study, Schering-Plough is currently enrolling patients in two large global Phase III clinical studies with vicriviroc administered once-daily as a single 30 mg tablet in adult treatment-experienced HIV patients with R5-type virus only.

The two ongoing Phase III studies, known as VICTOR-E3 and VICTOR-E4 (Vicriviroc in Combination Treatment with an Optimized Antiretroviral Therapy Regimen in HIV-Infected Treatment-Experienced Subjects), evaluate the virologic benefit of adding vicriviroc 30 mg once daily to an optimized background therapy compared to a control group receiving new optimized background therapy alone. The optimized background therapy must include at least two drugs to which the patient's HIV is susceptible. Patients coinfected with hepatitis B or C may be included in these studies and there are no exclusions of commonly prescribed drugs or need for dose adjustments based on the known vicriviroc drug-drug interaction profile. The two studies are currently enrolling approximately 375 patients each at more than 160 sites in North America, Latin America, Europe, Australia and South Africa.

For more information about the VICTOR-E3 and VICTOR-E4 clinical studies, please visit http://www.clinicaltrials.gov, search term: vicriviroc.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own bi
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine news :

1. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
2. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
3. Highmarks Hospital Pay-for-Performance Program Demonstrates Impressive Results
4. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
5. LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon
6. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
7. New Study Data Published in British Journal of Urology Demonstrates Cryoablation Effective for Kidney Cancer
8. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
9. First in the World Live Case Using New Technology Demonstrates Shorter Procedure Time
10. Study Shows Organons Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
11. US Preventive Medicine(R) Says Study on Heart Disease-related Deaths Demonstrates Need for Preventive Medical Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...ty illnesses common, study shows , , MO...ders are common among young adults in the United S... , To reach this finding, U.S. researchers anal...9 to 25, who took part in the National Epidemiolog...The study found that 45.8 percent of the 2,188 col...
(Date:12/1/2008)...ritis Foundation announces the 2008 winners of the.... The recipients, Dr. Gerard Karsenty of the Colum...l Nussenzweig of Rockefeller University received t... in the cure and control of rheumatic diseases. ,...the development and function of the skeletal syste...
(Date:12/1/2008)...-FirstCall/ -- Senetek PLC,(OTC Bulletin Board: S...elopment of technologies that target the science o...oup AG, specialists in the fields of strategic,de...ith offices in Zurich,Bern and Geneva has publis... Research Report, available in the "Investors" sec...
(Date:12/1/2008)...er (PTSD) affects as many as one in five of all Am...pe, assault, war or terrorism. It has emotionally ...s, families. , There is no broadly accepted tre... disorder, but thanks to a Tel Aviv University res... just around the corner. , Prof. Joseph Zohar fr...
Breaking Medicine News(10 mins):Health News:Few Young Adults Seek Treatment for Psych Disorders 2Health News:Easing the stress of trauma 2
...Abuse and Alcoholism (NIAAA), a part of the U.S. N... five distinct subtypes of alcoholism by analysin...alcohol dependence. Our findings should help disp... alcoholic, notes first author Dr. Howard B. Moss,...
...ial species into another by swapping their genomes...custom-built synthetic bugs, a pioneer on genetic...mapping the human genome, said a team of his resea...enetic code of one bacterial organism into another...
...evelopment (DFID) in Britain has announced a fund... years in support of the third phase of Governmen...e (NACP III). The NACP III is a comprehensive pr...e to halt and begin to reverse the AIDS epidemic i...
...e Apple electronics stores in US cities aiming to ...olest gadget on the planet, when they go on sale F...e, web browser and music player in the palm of the...6 p.m. (2200 GMT) Friday. Late Thursday some 60 f...
Other Medicine News:Health News:Researchers Identify Five Distinct Subtypes of Alcoholism 2Health News:Researchers Identify Five Distinct Subtypes of Alcoholism 3Health News:Replacing a Genome Boosts Race to Develop Designer Bugs: Study 2Health News:Replacing a Genome Boosts Race to Develop Designer Bugs: Study 3Health News:Tech Heads Go Gaga Waiting for Apple's IPhone 2
(Date:11/26/2008)... Children whose eyes are... increased risk of developing mental illness by ea...inic study published this month in Pediatrics , th...atrics. , , The retrospective study examine...mus (misaligned eyes) and compared them with recor...
(Date:11/25/2008)...dents against expanding statin use broadly in wake....J., Nov. 25 JUPITER, a clinical t...ascular risk of healthy patients with elevated CRP...adults, according to a national poll directed at h...part in the online poll conducted by medical news ...
(Date:11/25/2008)...wire-FirstCall/ -- CardioVascular,BioTherapeutics... that it has,dosed the first patient in North Ame...trial to treat patients with severe coronary heart...nt of CORonary heart Disease) trial will include,...doses in approximately 120,patients with severe c...
(Date:11/24/2008)...vation leadership and long-term commitment to hepa...4 Schering-Plough Corpor...ate on boceprevir, its lead investigational oral h...II development. The company believes boceprevir h...n-class protease inhibitor for treating chronic he...
Breaking Medicine Technology:Eye Divergence in Children Triples Risk of Mental Illness 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 2CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9The Ensign Group Successfully Graduates Troubled Nursing Home from CMS Special Focus Facility Program 12306 1The Ensign Group Successfully Graduates Troubled Nursing Home from CMS Special Focus Facility Program 12306 2The Ensign Group Successfully Graduates Troubled Nursing Home from CMS Special Focus Facility Program 12306 3Strengthening fluids with nanoparticles 3404 1Strengthening fluids with nanoparticles 3404 2Telik Announces Revised Date for Year End Financial Release Conference Call and Webcast 3401 1Tumor killing virus selectively targets diseased brain cells 12302 1Tumor killing virus selectively targets diseased brain cells 12302 2
... PALO ALTO, Calif., April 17, 2007 /PRNewswire-Fi... today of results from a,Phase 2 clinical trial of...de HCl, TLK286), carboplatin and paclitaxel in the...ung cancer. The,results include highly statistical...progression-free survival and overall survival,in ...
... - Findings Published in Blood Highlight Millenniu...rengthen the Role of VELCADE as,Foundation of Ther... CAMBRIDGE, Mass., April 17, 2007 /PRNewswire-Firs...ue of Blood show that a,team of researchers led by...iomarkers which may lead to identifying multiple,m...
Other Medicine Technology:Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 2Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 3Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 4Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection 2Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection 3Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection 4Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection 5Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection 6
Designed with a wider foot bed for comfort and stability. A low profile, rocker bottom helps promote natural gait and reduce plantar pressures. Cushioned inner and outer sole provides shock absorptio
Fracture walker designed to provide maximum comfort, protection and stability
AnkleWALKER™ Shorter uprights and circumferential plastic shell inhibit foot and ankle motion. Designed to provide comfortable stability for acute ankle sprains, soft tissue injuries, stress an
...ng brace specifically designed for foot and ankle ...l for patients whose limb length or calf circumfer...alker.,Each SP Walker is engineered for patient c... support, and edema reduction. The Walkers low roc...
Medicine Products: